Solid Biosciences Operating Income

Solid Biosciences (SLDB) currently reports a operating income of $-210M as of June 2026. That compares with $-160M in the prior-year period — down 35.3% year over year. Use the charts on this page to explore Solid Biosciences's operating income history and peer comparisons.

Solid Biosciences's operating income decreased from $-160M to $-210M — a 35.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Solid Biosciences reported $-210M in operating income as of June 2026. That compares with $-160M in the prior-year period — down 35.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-210M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Solid Biosciences, and consider following SLDB for alerts when major investors trade the stock.

Solid Biosciences is classified in the Healthcare sector. On operating income, it currently shows $-210M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SLDB with unrelated industries.